Director Higuchi Buys 150,000 LPCN Shares for $225,225 on the Open Market
LPCN is trading near its 52-week low of $1.36 (5.9% above the low) on light trading volume (0.1× avg).
Summary
Director John Higuchi bought 150,000 Lipocine shares for $225,225 at $1.49-$1.51 on November 19-20, raising his direct holdings to 391,365 shares. It is his largest purchase yet and follows a CEO buy earlier in November.
Key Events · Ownership and Investor Activity · LPCN
-
Director Buys 150,000 Shares
John Higuchi purchased 150,000 shares on the open market for $225,225 across two trades on November 19-20, 2026, at $1.49-$1.51 per share.
-
Stake Rises to 391,365 Shares
Post-transaction direct holdings stand at 391,365 shares, up from 241,365 after his early-October purchases.
-
Largest Buy in the Series
The $225,225 total is about four times his October 2 purchase of $55,043 and roughly eight times his October 1 purchase of $27,132.
-
Insider Accumulation Continues
Follows the CEO's 50,000-share open-market buy on November 12-13 for $79,487.50; the 90-day open-market tally shows $161,662 of net buying and no insider sales.
Analysis · LPCN · Life Sciences
Director John Higuchi put $225,225 of his own money into Lipocine across two open-market purchases at $1.49-$1.51, lifting his direct stake to 391,365 shares. That is roughly four times the size of his early-October buys and comes as the stock trades near the level of those purchases, so it reads as continued conviction rather than a one-off. It also extends a broader insider accumulation pattern: the CEO bought 50,000 shares on November 12-13, and the 90-day open-market tally now shows $161,662 of net buying with no insider sales.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LPCN was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $1.36 to $12.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.